Showing 781-790 of 1697 results for "".
- Pain Managementhttps://practicalneurology.com/diseases-diagnoses/headache-pain/0105-pain-management-pdf/31506/Recent developments over the past quarter have prompted significant reconsideration of the FDA’s approach to approving and monitoring new pain medications, particularly COX-2 selective anti-inflammatory agents. The catalyst for this shift was Merck’s global withdrawal of rofecoxib (Vioxx) in Septemb
- When and How to Discontinue AED Therapy in People with Epilepsyhttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn1007Epilepsy-pdf/31115/Discontinuation of Antiepileptic Drugs: Balancing Benefits and RisksAntiepileptic drugs (AEDs) have been the cornerstone of seizure disorder management for over seven decades, evolving from phenobarbital to more than two dozen agents. A critical question arises when patients achieve seizure freedom:
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn1007-dementia-pdf/31106/Caffeine, the most widely consumed psychoactive substance globally, continues to be a focal point in neurological research, particularly regarding its potential impact on cognitive decline and Alzheimer’s disease (AD). Recent studies presented in Practical Neurology highlight both promising and inco
- Pain Managementhttps://practicalneurology.com/diseases-diagnoses/headache-pain/pn0807-pain-mngmnt-pdf/31138/In the inaugural part of a two-part series, Dr. Charles Argoff explores the intricate relationship between neuropathic pain, sleep disturbances, and psychiatric disorders such as depression and anxiety. Neuropathic pain, arising from lesions or dysfunctions within the peripheral or central nervous s
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn0407-dementia-pdf/31186/As spring and summer travel seasons approach, attention often focuses on fuel prices and their impact on travel patterns. Analogously, the brain operates under a supply-and-demand framework for energy, where glucose and oxygen serve as essential “fuels.” When the brain’s energy demand surpasses supp
- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31140/Impact of SSRIs on Bone Health in Elderly Patients: Clinical InsightsRecent studies have raised concerns about the use of selective serotonin reuptake inhibitors (SSRIs) and their potential negative effects on bone health in older adults. These findings pose important considerations for neurologists
- Should Migraine Patients Undergo PFO Closure?https://practicalneurology.com/diseases-diagnoses/headache-pain/pn1206pfo-fea-pdf/31242/The relationship between patent foramen ovale (PFO) and migraine, particularly migraine with aura (MA), has garnered significant attention in neurology. PFO, a remnant of fetal circulation, persists in approximately 25% of adults, while migraines affect about 11% of the population. The concurrent pr
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31434/The resurgence of the antiplatelet resistance debate has rekindled discussions within the stroke care community, particularly concerning the optimal aspirin dosage for stroke prophylaxis. Historically, low-dose aspirin (≤325 mg) has been deemed as effective as higher doses in preventing both cardiov
Blood-Based Biomarkers in Alzheimer Disease: Clinical Implementation and Limitations
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/blood-based-biomarkers-in-alzheimer-disease-clinical-implementation-and-limitations/32100/Although biomarkers for Alzheimer disease have the potential to improve evaluation and care, barriers to implementation remain.Medical Marijuana: Composition, Neurological Benefits, And Adverse Events
https://practicalneurology.com/diseases-diagnoses/headache-pain/medical-marijuana-composition-neurological-benefits-and-adverse-events/30512/Exploring the potential benefits of medical marijuana in neurology and future directions in care.